CWS Financial Advisors LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

CWS Financial Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,702 shares of the biopharmaceutical company’s stock after buying an additional 855 shares during the period. CWS Financial Advisors LLC’s holdings in Gilead Sciences were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC lifted its position in Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company’s stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 94,646 shares of company stock valued at $11,311,286. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Needham & Company LLC upped their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday. BMO Capital Markets increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a report on Friday, October 31st. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $129.13.

Gilead Sciences Trading Down 0.1%

Shares of NASDAQ:GILD opened at $125.02 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The stock has a market cap of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. The business has a 50-day moving average price of $117.44 and a 200-day moving average price of $112.77.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.